Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study

Background: Microthrombosis and large-vessel thrombosis are the main triggers of COVID-19 worsening. The optimal anticoagulant regimen in COVID-19 patients hospitalized in medical wards remains unknown. Objectives: To evaluate the effects of intermediate-dose vs. standard-dose prophylactic anticoagulation (AC) among patients with COVID-19 hospitalized in medical wards. Methods and results: We used a large French multicentric retrospective study enrolling 2,878 COVID-19 patients hospitalized in medical wards. After exclusion of patients who had an AC treatment before hospitalization, we generated a propensity-score-matched cohort of patients who were treated with intermediate-dose or standard-dose prophylactic AC between February 26 and April 20, 2020 (intermediate-dose, n = 261; standard-dose prophylactic anticoagulation, n = 763). The primary outcome of the study was in-hospital mortality; this occurred in 23 of 261 (8.8%) patients in the intermediate-dose group and 74 of 783 (9.4%) patients in the standard-dose prophylactic AC group (p = 0.85); while time to death was also the same in both the treatment groups (11.5 and 11.6 days, respectively, p = 0.17). We did not observe any difference regarding venous and arterial thrombotic events between the intermediate dose and standard dose, respectively (venous thrombotic events: 2.3 vs. 2.4%, p=0.99; arterial thrombotic events: 2.7 vs. 1.2%, p = 0.25). The 30-day Kaplan–Meier curves for in-hospital mortality demonstrate no statistically significant difference in in-hospital mortality (HR: 0.99 (0.63–1.60); p = 0.99). Moreover, we found that no particular subgroup was associated with a significant reduction in in-hospital mortality. Conclusion: Among COVID-19 patients hospitalized in medical wards, intermediate-dose prophylactic AC compared with standard-dose prophylactic AC did not result in a significant difference in in-hospital mortality.

[1]  Á. Avezum,et al.  Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial , 2021, The Lancet.

[2]  S. Flanders,et al.  Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19 , 2021, JAMA network open.

[3]  T. Mirault,et al.  Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance , 2021, Angiogenesis.

[4]  G. Lip,et al.  Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial , 2021, Thrombosis and Haemostasis.

[5]  Jared L. Johnson,et al.  Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry , 2021, bioRxiv.

[6]  J. Alsac,et al.  Anticoagulation Before Hospitalization Is a Potential Protective Factor for COVID‐19: Insight From a French Multicenter Cohort Study , 2021, Journal of the American Heart Association.

[7]  M. Ohana,et al.  Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study , 2021, Annals of Intensive Care.

[8]  F. Pène,et al.  Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality , 2021, Angiogenesis.

[9]  D. Jiménez,et al.  Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019 , 2020, Chest.

[10]  E. Messas,et al.  Prevalence and characteristics of pulmonary embolism in 1042 COVID-19 patients with respiratory symptoms: A nested case-control study , 2020, Thrombosis Research.

[11]  S. Nopp,et al.  Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis , 2020, Research and Practice in Thrombosis and Haemostasis.

[12]  T. Ortel,et al.  ISTH DIC subcommittee communication on anticoagulation in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[13]  J. Alsac,et al.  D-dimers at hospital admission for COVID-19 are associated with in hospital mortality independently of venous thromboembolism: Insight from a French multicenter cohort study , 2020 .

[14]  Simon A. Jones,et al.  Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. , 2020, JAMA.

[15]  T. Mirault,et al.  Respiratory mechanics and gas exchanges in the early course of COVID-19 ARDS: a hypothesis-generating study , 2020, Annals of Intensive Care.

[16]  A. Cohen,et al.  Pulmonary embolism in COVID-19 patients: a French multicentre cohort study , 2020, European heart journal.

[17]  D. Huet,et al.  Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring , 2020, Critical Care.

[18]  D. Lebeaux,et al.  Curative anticoagulation prevents endothelial lesion in COVID‐19 patients , 2020, Journal of Thrombosis and Haemostasis.

[19]  E. Messas,et al.  Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients , 2020, Angiogenesis.

[20]  Axel Haverich,et al.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.

[21]  H. Merdji,et al.  Prothrombotic phenotype in COVID-19 severe patients , 2020, Intensive Care Medicine.

[22]  D. Smadja,et al.  Is COVID-19 a New Hematologic Disease? , 2020, Stem Cell Reviews and Reports.

[23]  Dengju Li,et al.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.

[24]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[25]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[26]  喬 嶋本.  Nested Case-control Study , 1992, Definitions.

[27]  J. Luban.  SARS-CoV-2 , 2020 .